Fortress Biotech (FBIO) Amortization - Intangibles (2024 - 2026)
Fortress Biotech (FBIO) posted quarterly Amortization - Intangibles of $1.1 million for Q4 2025, up 15.67% year-over-year from $957000.0 in Q4 2024, and up 4.04% quarter-over-quarter from $1.1 million in Q3 2025.
Powered by 
Analysis
Fortress Biotech (FBIO) Amortization - Intangibles (2024 - 2026) Analysis & Trends
Fortress Biotech's Amortization - Intangibles history runs 2 years deep, the most recent figure standing at $1.1 million for Q4 2025.
- In Q4 2025, Amortization - Intangibles rose 15.67% year-over-year to $1.1 million; the TTM figure through Dec 2025 stood at $4.3 million (up 26.51% YoY), while the FY2025 annual figure was $4.3 million, up 26.47% from the prior year.
- Amortization - Intangibles for Q4 2025 stood at $1.1 million, up from $1.1 million in the prior quarter.
- The five-year high for Amortization - Intangibles was $1.1 million in Q4 2025, with the low at $814000.0 in Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 10 | Fortress Biotech | 86.15 Mn | -110.42 Mn | 12.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 969,000.00 |
| Dec 31, 2025 | 1.11 Mn |
| Sep 30, 2025 | 1.06 Mn |
| Jun 30, 2025 | 1.06 Mn |
| Mar 31, 2025 | 1.07 Mn |
| Dec 31, 2024 | 981,000.00 |
| Sep 30, 2024 | 814,000.00 |
| Jun 30, 2024 | 814,000.00 |
| Mar 31, 2024 | 814,000.00 |